Background The open-label RECOVERY study reported improved survival in hospitalized,
SARS-CoV-2 seronegative patients treated with casirivimab and imdevimab (CAS + IMD). …

We conducted a post hoc analysis in seropositive patients who were negative or borderline
for functional neutralizing antibodies (NAbs) against severe acute respiratory syndrome …

Background Hospitalized patients with Covid-19 experience high mortality rates, ranging
from 10-30%. Casirivimab and imdevimab (REGEN-COV ® ) is authorized in various …

Objectives Simultaneous pancreas and kidney transplant (SPK) is the most effective treatment
for patients with type 1 diabetes mellitus and renal failure. However, the effect of ethnicity …

We conducted a post-hoc analysis in seropositive patients who were negative or borderline
for functional neutralizing antibodies (nAbs) against SARS-CoV-2 at baseline from a phase 1/…

Background Casirivimab and imdevimab (CAS/IMDEV) is authorized for emergency use in
the US for outpatients with COVID-19. We present results from patient cohorts receiving low …

This paper considers estimating the model coefficients when the observed periodic
autoregressive time series is contaminated by a trend. The proposed Yule–Walker estimators are …

… by Jingning Mei … Copyright 2016, Jingning Mei This document is copyrighted material. Under
copyright law, no … Jingning Mei Submitted to the Graduate Faculty as partial fulfillment of the …

Background: Hospitalized patients with Covid-19 experience high mortality rates, ranging from
10-30%. Casirivimab and imdevimab (REGEN-COV) is authorized in various jurisdictions …

Introduction: In current guidelines congestive heart failure (CHF) is an indication for renal
artery stenting, however there is no data on the utility of stenting for the prevention of CHF. We …